OBI received the reply from FDA about the Investigational Device Exemption (IDE) of Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424

1. Date of occurrence of the event: Nov 23, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4. Reciprocal shareholding ratios: not applicable 5. Cause of occurrence: OBI received a notification from FDA about the investigational device exemption (IDE) for ‘testing immunohistochemistry (IHC) of […]